Davis Polk advised the representatives of the initial purchasers on two Rule 144A/Regulation S offerings by Mylan N.V. of $500 million aggregate principal amount of its 3.000% senior notes due 2018 and $500 million aggregate principal amount of its 3.750% senior notes due 2020.

Mylan N.V. (“Mylan”) is a global pharmaceutical company committed to setting new standards in health care. Mylan offers a growing portfolio of around 1,400 generic and branded pharmaceuticals and several brand medications. In addition, Mylan offers a wide range of antiretroviral therapies on which nearly 50% of people being treated for HIV/AIDS in the developing world depend. Mylan also operates one of the largest active pharmaceutical ingredient manufacturers and currently markets products in about 165 countries and territories.

The Davis Polk capital markets team included partner John B. Meade and associates Yasin Keshvargar and Stephanie M. Rohlfs. The intellectual property team included counsel David R. Bauer. The U.S. tax team included counsel Alon Gurfinkel and associate Vinay Prabhakar. The U.K. tax team included partner Jonathan Cooklin, counsel David Wilson and associate Dominic Foulkes. Members of the Davis Polk team are based in the New York and London offices.

Copy link to share post